Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection

Gemma D. Banham,1,2 Alexandra Godlee,2,3 Sian E. Faustini,4 Adam F. Cunningham,4 Alex Richter,2,4 and Lorraine Harper2,5 on behalf of the COVID-HD Birmingham Study Group

1 Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
2 University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom
3 Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
4 Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
5 Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have disproportionately affected patients receiving in-center hemodialysis. In England, 11.3% of patients on in-center hemodialysis were reportedly infected by coronavirus disease 2019 (COVID-19), with a 23% fatality rate,1 45 times greater than in nonhemodialysis, age-matched populations.2 Nevertheless, little is known about antibody responses induced by infection and whether these associate with protection.

We report a single-center observational cohort study of 990 patients on hemodialysis, performed between March 10, 2020 and January 9, 2021. We measured the longevity of serological responses to SARS-CoV-2 infection and the risk of reinfection. Participants were recruited from the in-center hemodialysis population at University of Birmingham Hospitals National Health Service (NHS) Foundation Trust. SARS-CoV-2 infection waves were defined as first wave, March to July 2020 and second wave October 2020 to January 2021. Antibodies (combined IgG, IgA, and IgM; IgGAM) against SARS-CoV-2 spike glycoprotein were examined by ELISA in surplus serum from routine clinical samples taken during the first wave.3 We modeled antibody responses longitudinally using generalized estimating equations, allowing for sampling variation between individuals (Supplemental Material). Frequency of PCR-confirmed SARS-CoV-2 infection during the second wave was analyzed according to antibody status.

Clinical data and SARS-CoV-2 infection status were collated from electronic medical records. SARS-CoV-2 infection onset date was defined as the date symptoms started or a positive PCR (PCR+) test, whichever was earlier. In patients testing antibody positive without a history of SARS-CoV-2 infection, the predicted onset date was defined as the date 50% of patients who were symptomatic had developed SARS-CoV-2 within their hemodialysis unit.

Antispike SARS-CoV-2 antibodies were detected in 25.9% (256 out of 990) of patients from the first wave of COVID-19, with 54.7% seroconverting without a history of infection (140 out of 256) (Table 1). In total, 15 patients with PCR-confirmed COVID-19 had no evidence of an antibody response. Six of these 15 patients died after a PCR+ test (median 4 days, range 1–5 days) and six patients had no samples after 14 days after a PCR+ test. Excluding these 12 patients with insufficient samples for analysis, 96% (82 out of 85) of patients who were PCR+ for generated an antibody response.

We investigated whether antibodies generated against SARS-CoV-2 persist in patients receiving hemodialysis. In total, 174 patients provided additional samples after testing positive; of these, 132 (75.9%) remained antibody positive at the last sample (median duration 124 days after infection, interquartile range, 95–210). Modeling of our data showed the predicted mean IgGAM antispike response remained positive >200 days after infection but declined over time (Figure 1). Those with symptomatic disease had higher predicted mean IgGAM responses than asymptomatic individuals ($P=0.004$).

During the second wave, patients were screened routinely for infection. In total, 90 PCR+ patients were...
Table 1. Comparing outcome, comorbidity, and demographic variables dependent on detection of SARS-CoV-2 antibodies

<table>
<thead>
<tr>
<th>Variables</th>
<th>All n=990</th>
<th>AB+ n=734</th>
<th>AB– n=256</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male, n (%)</td>
<td>579 (58.5)</td>
<td>447 (60.9)</td>
<td>132 (51.6)</td>
<td>0.009</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>411 (41.5)</td>
<td>287 (39.1)</td>
<td>124 (48.4)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.006</td>
</tr>
<tr>
<td>White</td>
<td>481 (48.6)</td>
<td>381 (51.9)</td>
<td>100 (39.1)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>296 (29.9)</td>
<td>201 (27.4)</td>
<td>95 (37.1)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>142 (14.3)</td>
<td>100 (13.6)</td>
<td>42 (16.4)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>35 (3.5)</td>
<td>24 (3.3)</td>
<td>11 (4.3)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>36 (3.6)</td>
<td>28 (3.8)</td>
<td>8 (3.1)</td>
<td></td>
</tr>
<tr>
<td>Age, yrs, median (IQR)</td>
<td>65 (54–75)</td>
<td>64 (54–75)</td>
<td>67 (55–75)</td>
<td>0.482</td>
</tr>
<tr>
<td>IMD, decile, median (IQR)</td>
<td>2 (1–5)</td>
<td>2 (1–5)</td>
<td>2 (1–4)</td>
<td>0.096</td>
</tr>
<tr>
<td>BMI, kg/m² median (IQR)</td>
<td>27 (23–32)</td>
<td>27 (23–31)</td>
<td>27 (24–32)</td>
<td>0.228</td>
</tr>
<tr>
<td>CCI, median (IQR)</td>
<td>7 (5–8)</td>
<td>7 (5–8)</td>
<td>7 (6–8)</td>
<td>0.024</td>
</tr>
<tr>
<td>DM, n (%)</td>
<td>418 (42.2)</td>
<td>288 (39.2)</td>
<td>130 (50.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>Immunosuppression medication, n (%)</td>
<td>155 (15.7)</td>
<td>120 (16.3)</td>
<td>35 (13.7)</td>
<td>0.310</td>
</tr>
<tr>
<td>Symptoms reported, n (%)</td>
<td>227 (22.9)</td>
<td>111 (15.1)</td>
<td>116 (45.3)</td>
<td>0.000</td>
</tr>
<tr>
<td>Hospitalized, n (%)</td>
<td>128 (12.9)</td>
<td>57 (7.8)</td>
<td>71 (27.7)</td>
<td>0.000</td>
</tr>
<tr>
<td>Died, n (%)</td>
<td>93 (9.4)</td>
<td>66 (9.0)</td>
<td>27 (10.5)</td>
<td>0.463</td>
</tr>
<tr>
<td>Alive at the start of the second wave</td>
<td>n=700</td>
<td>n=237</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCR+ during second wave, n (%)</td>
<td>80 (11.4)</td>
<td>10 (4.2)</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Immunosuppression medication, n (%)</td>
<td>8 (10.0)</td>
<td>1 (10.0)</td>
<td>1.000</td>
<td></td>
</tr>
<tr>
<td>Symptoms reported, n (%)</td>
<td>57 (71.3)</td>
<td>5 (50.0)</td>
<td>0.171</td>
<td></td>
</tr>
<tr>
<td>Hospitalized, n (%)</td>
<td>34 (42.5)</td>
<td>4 (40.0)</td>
<td>0.880</td>
<td></td>
</tr>
<tr>
<td>Died, n (%)</td>
<td>10 (12.5)</td>
<td>2 (20.0)</td>
<td>0.511</td>
<td></td>
</tr>
</tbody>
</table>

Antibody status determined during the first wave. P values from chi-squared tests for categorical data and Wilcoxon rank-sum tests for continuous data. Current use of immunosuppression medication or intravenous agent within a year of the start of the first wave. Symptoms reported compatible with SARS-CoV-2 infection. Death by January 9, 2021. PCR positivity during the second wave is reported as a percentage of those patients alive at the beginning of the second wave, with associated presence immunosuppression, symptoms, hospitalization, and death reported as a percentage of those who are PCR+ AB+. AB+ SARS-CoV-2 antispike IgGAM seropositive; IQR, interquartile range; IMD, Index of Multiple Deprivation 2019; BMI, body mass index; CCI, Charlson Comorbidity Index; DM, diabetes mellitus.

Figure 1. The serological response to SARS-CoV-2 and the risk of reinfection. Gray and red lines represent individual antibody ratios over time for patients who were antibody positive during the first wave and alive at the start of the second wave. Patients testing PCR+ during the second wave are shown by red lines. Patients who did not test PCR+ during the second wave are shown by gray lines. The predicted mean IgGAM serological response for the cohort is shown by solid black lines. The threshold for antibody positivity is represented by a dotted line. Eight of the 10 patients with antibodies detected in the first wave, who tested PCR+ during the second wave, had antibody ratios lower than the predicted mean for the cohort (range 65–192 days between last IgGAM and PCR+ tests) (Figure 1).

In this hemodialysis cohort, antibody responses to the SARS-CoV-2 spike protein are maintained, as in other cohorts, and may be associated with a reduced frequency of re-infection. Those with lower levels of antibodies appear to be at greater risk of re-infection. Our analysis is limited to the quantification of antibody responses; assessment of the neutralizing
Infections were detected among 1265 care workers; only two asymptomatic existing antibodies, whereas in healthcare patients in 4.2% (10 out of 237) of participants, the immune response is protective against reinfection.

We confirmed SARS-CoV-2 infection in 4.2% (10 out of 237) of patients on hemodialysis with pre-existing antibodies, whereas in health care workers only two asymptomatic infections were detected among 1265 antibody-positive participants. The different infection rate is, perhaps, unsurprising given the significant immunosuppression associated with hemodialysis, differences in testing frequency, the age disparity between the studied groups, and potential differences in symptom expression but this requires further investigation.

This is a large hemodialysis cohort; however, the analysis does have limitations. We were unable to collect samples from most patients who died early in the pandemic, who may not have developed a robust antibody response. Due to our sampling strategy, we were unable to describe the maturation of the immune response comprehensively for an individual from time of infection; however, we used generalized estimating equations to allow for this. Early sampling was biased toward those with symptoms, and we may have missed individuals showing short-lived responses while asymptomatic.

In conclusion, patients on hemodialysis who survive SARS-CoV-2 infection generate an antibody response that is well maintained and appears to be associated with a reduced frequency of reinfection. Given patients with lower responses may be at increased risk of reinfection, the capacity of antivaccine antibody responses to protect patients on hemodialysis should be closely monitored to determine efficacy.

**DISCLOSURES**

A. Cunningham reports consultancy agreements with Pfizer - vaccine education, Sanofi - vaccine education, and Oxford Immunotec - Immunology education; research funding from GSK - vaccine research; honoraria from Oxford Immunotec; and scientific advisor or membership via BSI, Microbiology Society, and BactiVac. A. Richter reports research funding from Risk-Free Behring. L. Harper reports research funding from Novartis, Talaris, GSK, Vifor, and Chemocentryx; and honoraria from Novartis, Chemocentryx, and Roche. All remaining authors have nothing to disclose.

**FUNDING**

This work was supported by funding for regents from the Queen Elizabeth Hospital Birmingham Charity grant 16-3-046.

**ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

Ethical approval was granted by the North West Preston Research Committee (ref 20/NW/0240 IRAS Project ID: 282164) for the NIHR UPH Coronavirus Immunological Analysis study.

**ACKNOWLEDGMENTS**

Dr. G. Banham, Prof. A. Cunningham, Prof. L. Harper, and Prof. A. Richter designed the study; Dr. G. Banham and Dr. A. Godlee were involved in data collection and analysis; Dr. S. Faustini and Prof. A. Richter performed the experiments; Dr. G. Banham and Dr. A. Godlee prepared the figures; Dr. G. Banham, Prof. A. Cunningham, Dr. A. Godlee, Prof. L. Harper, and Prof. A. Richter drafted and revised the paper; and all authors approved the final version of the manuscript. We thank Dr. Anna L. Casey, Liz Ratcliffe (Department of Pathology, University Hospitals Birmingham NHS Foundation Trust) for sample collection; Claire Backhouse, Beena Emmanuel, Lynsey A Dunbar (Clinical Immunology Service, University Hospitals Birmingham) for processing samples; Dr. Matthew Tabinor and Dr. Megan Fahy (University Hospitals Birmingham NHS Foundation Trust) for assistance with data collection; Dr. Peter Nightingale (University Hospitals Birmingham NHS Foundation Trust) for providing statistical oversight; Prof. Paul Moss (Institute of Immunology and Immunotherapy, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust), the Chief Investigator of the CIA Study, for arranging ethical approval and for his input in study design and Dr. Stephanie Stringer (University Hospitals Birmingham NHS Foundation Trust), the clinical lead for the hemodialysis service, for coordinating the COVID-19 response. None of these individuals received compensation for their contribution. We would like to thank the Department of Pathology, University Hospitals Birmingham NHS Foundation Trust, and the Clinical Immunology Service, University of Birmingham, for processing samples, together with the medical teams and dialysis nurses who cared for these patients.

**SUPPLEMENTAL MATERIAL**

This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2021020188/-/DCSupplemental.

**REFERENCES**

Supplement

Haemodialysis patients make long-lived antibodies against SARS-CoV-2 that may be associated with reduced re-infection

Dr Gemma D Banham MRCP PhD 1,5*, Dr Alexandra Godlee BM BCh PhD 2,5*, Dr Sian E Faustini PhD 3, Prof Adam F Cunningham PhD 3, Prof Alex Richter FRCPath MD 3,5, Prof Lorraine Harper PhD FRCP 4,5 on behalf of the COVID-HD Birmingham Study Group

1. Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham

2. Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham

3. Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham

4. Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham

5. University Hospitals Birmingham NHS Foundation Trust

*contributed equally
Table of Contents

Serological testing 3
Statistical analysis 3
References 5
Serological testing

Antibodies (combined IgG, IgA and IgM (IgGAM)) against the SARS-CoV-2 spike glycoprotein were measured using a CE marked, validated, commercially available ELISA (Product code: MK654, The Binding Site (TBS), Birmingham), as previously described (1), as per manufacturer’s instructions. Prior validation of this assay has shown it demonstrates 100% sensitivity in individuals with PCR-proven disease 7 days post symptom onset (n=59 hospitalised, n=31 community) and 97.8% specificity based on 270 individual negative pre-2019 samples from commercial sources (2).

Statistical analysis

Demographic data was summarised as means and standard deviations for normally distributed data, medians and (interquartile) ranges for non-parametric data and counts and percentages for categorical data.

Due to the variable number of samples and sampling times for each patient, we used generalised estimating equations (GEE) with an exchangeable correlation structure to model mean antibody responses over time. Predicted mean serological responses were calculated from the complete dataset - 650 samples from 256 antibody positive patients. We hypothesised that the mean antibody ratio would rise to a peak and then fall. We proposed the simplest model that could be used to reflect our hypothesis - a line representing the initial rise in antibody ratio (the upslope) and a second line representing the fall (the downslope).

Our model included time as a continuous independent variable, an indicator variable to denote whether each time was before or after the turning point and an interaction between
these two variables to allow for the upslope and downslope. The position of the turning point was varied in candidate models and the lowest quasi-likelihood under independence model criterion (QIC) was used to select the final model. This final model was used for the prediction of the mean antibody ratio at any given timepoint. The data were log transformed to achieve normality (as assessed by Q-Q plots of the generated residuals). The resulting predicted mean appears as two curves when represented on the original linear scale.

For comparisons within the cohort, the GEE model was extended to include the grouping variable and its interactions with the other variables in the model. The significance of the grouping variable was assessed via Wald Chi-Squared tests in terms of the main effect, the two-way interactions and the three-way interaction. Where interactions were found to be non-significant, they were removed from the model in a stepwise fashion to generate the simplest model.

Comparisons were made using Wilcoxon Rank tests for non-parametric data; Chi-squared tests for categorical data; Wald Chi-squared tests for variables within GEE models. P-value <0.05 were deemed statistically significant.

Generalised estimating equations were performed using SPSS Version 26 (IBM). All other analyses were performed using STATA Version 16 (StataCorp).
References:
